Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James G Greger

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Proceedings of the National Academy of Sciences of the United States of America|April 8, 2003
Evidence that the retroviral DNA integration process triggers an ATR-dependent DNA damage responseRené Daniel, Gary Kao, Konstantin Taganov, et al.
The Journal of Biological Chemistry|August 17, 2004
Histone H2AX is phosphorylated at sites of retroviral DNA integration but is dispensable for postintegration repairRené Daniel, Joseph Ramcharan, Emmy Rogakou, et al.
Journal of Virology|January 5, 2007
High-frequency epigenetic repression and silencing of retroviruses can be antagonized by histone deacetylase inhibitors and transcriptional activators, but uniform reactivation in cell clones is restricted by additional mechanismsRichard A Katz, Emily Jack-Scott, Anna Narezkina, et al.
Molecular Cancer Therapeutics|March 6, 2012
Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutationsJames G Greger, Stephen D Eastman, Vivian Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2013
Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trialHatem A Azim, Dominique Agbor-Tarh, Ian Bradbury, et al.
Cancer Immunology, Immunotherapy : CII|August 6, 2024
Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumorsRavit Geva, Maria Vieito, Jorge Ramon, et al.
Cancer Chemotherapy and Pharmacology|March 17, 2022
First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancersEnriqueta Felip, Victor Moreno, Daniel Morgensztern, et al.
Iscience|March 10, 2025
JNJ-78306358, a first-in-class bispecific T cell engaging antibody targeting CD3 and HLA-GNataša Obermajer, Adam Zwolak, Kelly van de Ven, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Proceedings of the National Academy of Sciences of the United States of America|April 8, 2003
Evidence that the retroviral DNA integration process triggers an ATR-dependent DNA damage responseRené Daniel, Gary Kao, Konstantin Taganov, et al.
The Journal of Biological Chemistry|August 17, 2004
Histone H2AX is phosphorylated at sites of retroviral DNA integration but is dispensable for postintegration repairRené Daniel, Joseph Ramcharan, Emmy Rogakou, et al.
Journal of Virology|January 5, 2007
High-frequency epigenetic repression and silencing of retroviruses can be antagonized by histone deacetylase inhibitors and transcriptional activators, but uniform reactivation in cell clones is restricted by additional mechanismsRichard A Katz, Emily Jack-Scott, Anna Narezkina, et al.
Molecular Cancer Therapeutics|March 6, 2012
Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutationsJames G Greger, Stephen D Eastman, Vivian Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2013
Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trialHatem A Azim, Dominique Agbor-Tarh, Ian Bradbury, et al.
Cancer Immunology, Immunotherapy : CII|August 6, 2024
Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumorsRavit Geva, Maria Vieito, Jorge Ramon, et al.
Cancer Chemotherapy and Pharmacology|March 17, 2022
First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancersEnriqueta Felip, Victor Moreno, Daniel Morgensztern, et al.
Iscience|March 10, 2025
JNJ-78306358, a first-in-class bispecific T cell engaging antibody targeting CD3 and HLA-GNataša Obermajer, Adam Zwolak, Kelly van de Ven, et al.
Pageof 2